Scholarlink

Objective <p>Estrogen-containing oral contraceptives (OCPs) increase the risk of thromboembolic events including cerebral venous sinus thromboses (CVSTs). However, robust pharmacovigilance data comparing CVST risk across OCPs remain limited.</p> Study design <p>The FDA Adverse Event Reporting System (FAERS) was used to investigate which OCPs are associated with a disproportionally high CVST reporting.</p> Results <p>There were 479 reports of CVST across OCPs. Estrogen containing contraceptives were associated with disproportionally high CVST reporting, with ethinyl estradiol + drosperinone exhibiting the most substantial association (reporting odds ratio: 38.1, 345 cases).</p> Conclusion <p>Clinicians should educate those taking estrogen-containing OCPs on&#xa0;how to identify CVST symptoms.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cerebral venous sinus thrombosis risk across various oral contraceptives: a disproportionality analysis of the FDA adverse event reporting system

  • 期刊论文

  • 发表日期：

    2026年5月15日

查看全文
  • Alexandra Balshi

摘要

Objective

Estrogen-containing oral contraceptives (OCPs) increase the risk of thromboembolic events including cerebral venous sinus thromboses (CVSTs). However, robust pharmacovigilance data comparing CVST risk across OCPs remain limited.

Study design

The FDA Adverse Event Reporting System (FAERS) was used to investigate which OCPs are associated with a disproportionally high CVST reporting.

Results

There were 479 reports of CVST across OCPs. Estrogen containing contraceptives were associated with disproportionally high CVST reporting, with ethinyl estradiol + drosperinone exhibiting the most substantial association (reporting odds ratio: 38.1, 345 cases).

Conclusion

Clinicians should educate those taking estrogen-containing OCPs on how to identify CVST symptoms.